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Conclusions
Pancreatic fluid tolerance.
Tolerance test perfomed in
NaHCO3 with 1.9 mg/ml
pancreatin for 3h. Cell
counts compared to type
strain grown in the same
condition (mean ± sd, N =
3).
Effect of bile salts after low
pH treatment. Bile acid
(Oxbile) treatment
perfomed in MRS over time
after pH 2.5 exposure (3h)
(mean ± sd, N = 3).
Growth rate with bile
salts. Bile acid (Oxbile)
treatment perfomed in
MRS over time (mean ±
sd, N = 3).
Lactobacillus brevis FEM 1874 was confirmed as a high GABA producing strain with potential as a probiotic for human use, given
it’s ability to survive under simulated gastro-intestinal physicochemical conditions. However, its ability to produce GABA within
the gut and consequently mediate health benefits via the gut:brain axis and immune system, must further be confirmed in vivo.
Bile Salt Hydrolysis (BSH)
assay. BSH activity
perfomed on MRS agar
plates supplemented with
0.5% of bile acids. (mean ±
sd, N = 3).
Acid tolerance (pH 2, 2.5,
3.2). Acid treatment
perfomed in PBS at 0 and 3h
(T0 and T3 resp). Cell counts
compared to type strain
grown in the same condition
(mean ± sd, N = 3).
1) FEM 1874 survives in gastrointestinal phisicochemical condition
Results
3) FEM 1874 GABA genes sequences analysis and knock-out generation strategy
Probiotics and their metabolites can act as brain modulators through the gut:brain
axis system. In this respect γ-aminobutyric acid (GABA) gut bacteria produced, has
been identified as a possible factor improving brain function, inhibiting inflammation
and regulating energy metabolism.
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GABA production (mg/L) after
24h in experimental buffer +
glutamate [1mg/ml]. Total
isolate considered 110. Mean
± sd, N = 3.
GABA production. GABA
production after 24h in
experimental buffer +
glutamate [1mg/ml]. Mean
± sd, N = 3
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FEM 1874 GABA genes sequenced: 100% identity. Based on L. brevis ATCC 367 gene
sequencing, nine sets of primer were used to sequence all GABA genes. 100% of
identity was found, only a SNP in antiporter (gad C) with synonimus mutation (V to V)
were evidenced.
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Schematic representation of the strategy
employed in the study for the cintruction of the
pUC19-gad gene-erm vectors.
“Wild” Alpine cheese isolate Lactobacillus brevis FEM 1874 was characterized for
potential probiotics traits and GABA production. Acid, bile and pancreatic fluid
resistance was assessed and the genetic loci for GABA production and export
characterized for the subsequent knock-out vectors construction.
2) FEM 1874 produced high GABA level
Probiotic potential of a high GABA producing strain, 
Lactobacillus brevis FEM 1874, isolated from traditional 
“wild” Alpine cheese.
Strain BSH activity
L. brevis DSM 
20054
-
L. brevis FEM 
1874
+
Strain GABA (mg/L) sd
VSL#3 9.39 0.31
L. brevis DSM 
20054
78.2 18.6
L. brevis FEM 
1874
262.0 15.4
